Adib Kassas, MD
Psychiatry · Dubuque, IANPI 1386694156
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $358, 2.9 times the $123 reported in 2019.
Across 85 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$300
- Supernus Pharmaceuticals, Inc.$204
- Johnson & Johnson$138
- Otsuka America Pharmaceutical, Inc.$118
- Neurocrine Biosciences, Inc.$97
- Teva Pharmaceuticals USA, Inc.$73
- plus $514 from 13 others
What the payments were for
- Food & beverage$1,39096%
- Education$544%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $300 |
| Supernus Pharmaceuticals, Inc. | 16 | $204 |
| Johnson & Johnson | 10 | $138 |
| Otsuka America Pharmaceutical, Inc. | 6 | $118 |
| Neurocrine Biosciences, Inc. | 6 | $97 |
| Teva Pharmaceuticals USA, Inc. | 4 | $73 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $68 |
| Acadia Pharmaceuticals Inc | 4 | $67 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Livanova USA, Inc. | 2 | $55 |
| Indivior Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Alkermes, Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Lundbeck LLC | 2 | $29 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Corium, LLC | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Harmony Biosciences LLC | 1 | $9 |
How this compares
$1,444 in reported general payments places this provider in the 80th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 25 | $133,101 |
| VraylarCariprazine Hcl | 118 | $120,676 |
| FanaptIloperidone | 17 | $37,017 |
| Invega SustennaPaliperidone Palmitate | 13 | $30,509 |
| TrintellixVortioxetine Hydrobromide | 30 | $14,599 |
| Aripiprazole | 119 | $13,501 |
| Oxcarbazepine | 95 | $12,784 |
| Chlorpromazine Hcl | 22 | $9,432 |
| Propranolol Hcl ErPropranolol Hcl | 95 | $6,525 |
| Quetiapine Fumarate | 287 | $6,242 |
| StratteraAtomoxetine Hcl | 12 | $5,424 |
| Divalproex Sodium ErDivalproex Sodium | 87 | $5,342 |
| Paliperidone ErPaliperidone | 27 | $4,870 |
| Clozapine | 41 | $4,757 |
| Atomoxetine Hcl | 14 | $4,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $73 | $133,10125 claims |
| AbbVieVraylar | $300 | $120,676118 claims |
| Johnson & JohnsonInvega Sustenna | $138 | $30,50913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $32 | $18,87141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Dubuque
- Lee BermanDubuque$3K
- Michael PeroskiDubuque$2K
- Anupama UpadhyayDubuque$1K
- Peter SzeibelDubuque$891
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Jimmy MascaroOttumwa$361K
- Alan WhittersCedar Rapids$170K
- Donald BlackIowa City$19K
- William CoryellIowa City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.